Diagnostics & imaging AI · Chest and emergency radiology AI
Qure.ai
Qure.ai provides radiology AI algorithms that help hospitals prioritize critical findings on chest X-ray, CT, and related studies inside PACS worklists. It does not replace the radiologist.
Strong fit
- Hospitals and imaging networks that need AI triage for chest X-ray, CT, and emergency findings
- Buyers comparing mid-priced radiology AI vendors used around the world rather than US-only single-use tools
- Groups that want help ranking the worklist and making decisions without replacing the radiologist
Weak fit
- Clinics with no imaging volume and no way to connect to a PACS
- Buyers who only need bedside ultrasound AI for one set of devices
- Groups that will not allow any outside algorithm on diagnostic images
Bottom line
Qure.ai is worth using for health systems that want AI triage of chest and emergency radiology studies at moderate cost. It suits teams ready for PACS integration and clinical validation. U.S. acute care systems wanting broader orchestration may prefer Aidoc, and chest X-ray detection specialists may prefer Riverain.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Qure.ai is a radiology AI company founded in Mumbai and led by co-founder and CEO Prashant Warier. It has a few hundred employees.
Hospitals around the world use its FDA-cleared algorithms to flag and rank critical findings on chest X-rays, CTs, and related studies, inside the PACS worklists they use now.
The software supports radiologists rather than replacing them. It is not a PACS replacement or an AI note-taking tool.
Setup needs PACS and RIS connections and clinical testing, the usual effort for AI built into a PACS.
Pricing is per study or through a license for the whole organization.
Among the imaging AI tools we review, Qure.ai scores below Aidoc on how broadly it coordinates U.S. hospital care. It scores above smaller tools for one body area when the need is triage of many chest and brain findings.
Aidoc suits coordinating U.S. hospital care, and Riverain suits deep chest X-ray detection. AISAP suits bedside ultrasound AI rather than radiology worklist triage.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Aidoc | 7.9 | 7.5 |
| ScreenPoint Medical | 7.9 | 7.6 |
| Harrison.ai | 7.7 | 7.5 |
| Qure.ai | 7.4 | 7.1 |
| Optellum | 7.4 | 7.0 |
| Riverain Technologies | 7.3 | 6.9 |
| Subtle Medical | 7.2 | 6.8 |
| DeepTek | 7.1 | 6.8 |
| AZmed | 6.9 | 6.7 |
| Enlitic | 6.9 | 6.5 |
| Avicenna.AI | 6.9 | 6.6 |
| Ferrum Health | 6.8 | 6.5 |
| Koios Medical | 6.7 | 6.3 |
Pricing
| Item | Detail |
|---|---|
| Model | Radiology AI licenses per study or for the whole organization, quoted by imaging type and volume. |
| What usually drives cost | Study volume by imaging type, which algorithms you buy, regions covered, and support. |
| What to ask before you buy | Cost per study or yearly license at your chest and CT volume, including the PACS connection. |
| Published pricing | Qure.ai does not publish US prices. Quotes vary by organization and region. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Qure.ai to function | |
| An owner for the PACS and RIS connection | Algorithms need a way into the worklist. |
| A named radiologist to lead it | Alerts fail without clinical ownership. |
| A planned set of cases for testing | Skip testing and trust collapses. |
| IT security review for imaging AI | Imaging AI stalls without approval. |
| Escalation rules for critical findings | Ranking cases without a process creates legal risk. |
| What will maximize your value | |
| Try one imaging type first | Starting every imaging type on day one multiplies tickets. |
| Measure turnaround on critical studies | Shows whether triage helps. |
| Follow your current AI rules | Duplicate AI tools confuse radiologists. |
| Deal-breakers | |
| You have no imaging volume | |
| You will not allow outside imaging AI | |
| You cannot give access to PACS | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Integration and validation | 6-12 weeks |
| 2 | First imaging type | 4-8 weeks |
| 3 | Expansion | 8-16 weeks |
Leadership
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.